t(14;18), a journey to eternity

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• The t(14;18) chromosomal translocation is the most common aberration in follicular non-Hodgkin's lymphoma (NHL) and less frequent in diffuse large cell lymphoma (DLCL).
• This translocation leads to the deregulation of the bcl-2 proto-oncogene, which inhibits programmed cell death (PCD).
• A family of bcl-2-related genes exists, with members either protecting or promoting PCD, forming dimers that regulate cellular sensitivity to death signals (the rheostat model).

Purpose of the Study:

• To investigate the role and implications of the t(14;18) chromosomal aberration in non-Hodgkin's lymphoma.
• To explore the significance of bcl-2 deregulation and the rheostat model in lymphoma pathogenesis and treatment.
• To establish the t(14;18) as a lymphoma-specific marker for residual disease monitoring.

Main Methods:

• Analysis of chromosomal aberrations in follicular NHL and DLCL patient samples.
• Quantification of residual disease during treatment using the t(14;18) as a marker.
• Review of the bcl-2 gene family, protein dimerization, and the rheostat model in relation to PCD.

Main Results:

• The t(14;18) translocation does not significantly affect overall survival in follicular NHL or DLCL.
• The t(14;18) serves as a valuable lymphoma-specific marker for quantifying minimal residual disease during therapy.
• Deregulation of bcl-2 and altered expression of related genes impact the cellular rheostat, promoting chemotherapy resistance in malignancies.

Conclusions:

• The t(14;18) translocation is a critical diagnostic and monitoring tool in specific lymphoma subtypes.
• Understanding the bcl-2 rheostat model offers insights into therapeutic resistance mechanisms.
• The t(14;18) marker facilitates the evaluation of novel treatment protocols and residual disease management.